Intensity Therapeutics, Inc. Common stock (INTS) is a publicly traded Healthcare sector company. As of May 21, 2026, INTS trades at $4.63 with a market cap of $12.38M and a P/E ratio of -0.54. INTS moved +0.87% today. Year to date, INTS is -53.23%; over the trailing twelve months it is -55.35%. Its 52-week range spans $4.50 to $100.00. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces INTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
INTS financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. INTS recently traded at $4.63. Market cap is $12.38M. P/E ratio is -0.54. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $4.63 |
| Market Cap | $12.38M |
| P/E Ratio | -0.54 |
| EPS | $-8.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $100.00 |
| 52-Week Low | $4.50 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-11.61M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-11.61M | $-8.56 |
| 2024 | $0 | $-16.27M | $-1.17 |
| 2023 | $0 | $-10.54M | $-1.38 |
2 analysts cover INTS: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $25.00.